
On November 24, Chief Scientist Professor Wang Jianxun attended the 2023 12th China Innovation and Entrepreneurship Competition National Biomedicine Competition, guided by the Ministry of Science and Technology, the Ministry of Finance, the Ministry of Education, the Cyberspace Administration of China, and the All-China Federation of Industry and Commerce, and co-organized by the Office of the Organizing Committee of the China Innovation and Entrepreneurship Competition and the Beijing Guoke Small and Medium-Sized Enterprise Science and Technology Innovation Development Foundation, among other units. A total of 37,243 enterprises registered for this year's competition across 37 competition zones nationwide, including 5,937 biopharmaceutical enterprises. A total of 327 enterprises (249 in the Growth Group and 78 in the Startup Group) were shortlisted for this National Biomedicine Competition. Leveraging its breakthrough frontier technologies and comprehensive corporate strength, Shenzhen Cell Valley successfully advanced to the National Finals of the 12th China Innovation and Entrepreneurship Competition in September this year. After fierce competition, it stood out from among the many national competitors and was honored with the Outstanding Enterprise Award. Of the 20 shortlisted enterprises from Shenzhen, only 6 received awards.

The project presented by Shenzhen Cell Valley in this competition was "Establishment of an Industrial Production System for Cell-Based Drugs Based on Retroviral Vectors." As the only CRO/CDMO one-stop outsourcing service provider in China with industrial-grade retroviral vector technology (including the Pack-SS system), Shenzhen Cell Valley focuses on addressing the capacity and cost bottlenecks in large-scale production in the cell and gene therapy field. It fully leverages the advantages of its core pipeline—industrial-scale retroviral vector preparation—including low cost, high single-batch capacity, high transfection efficiency, strong stability, and broad infection range. The company has built a full-process, one-stop service industry chain for cell therapy drugs spanning early-stage R&D, clinical research, contract manufacturing, and talent cultivation, continuously improving service quality and product quality, and contributing to the development of national strategic science and technology in the life and health field.
Scan to follow our latest news Working hours: Monday to Friday, 9:00-18:00
Contact:Ms. Lai
Email:laijiaqi@rodael.com
Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)